Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence
Technology appraisal guidance
Reference number: TA810
Published:
Evidence
Review and download supporting evidence. Includes the full guideline if available.